Travere solo mark circle

Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Read the full press release >
Travere solo mark circle

Travere Therapeutics Provides Corporate Update and 2021 Outlook

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2020 to be approximately $51 million. Read the full press release >
Travere solo mark circle

Travere Therapeutics Virtual R&D Day

On December 9, Travere Therapeutics held a virtual R&D day to review the company’s key pipeline programs. The event featured presentations from external experts and the Travere Therapeutics senior management team. Watch the recorded webcast >
Rarecast logo

Eric Dube, Ph.D., Interviewed on Global Genes’ Rarecast Podcast

Eric Dube, Ph.D., Interviewed on Global Genes' Rarecast Podcast: With a New Identity, Travere Therapeutics Seeks to Find Its True Path Listen to the podcast >
Travere Circle Logo

Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, November 30, 2020 – SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition that often leads to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in the first quarter of 2021. Read the press release >
Rise for Rare - Black Women's Health Imperative

Travere Therapeutics Supports Rare Disease Diversity Coalition’s “Rise for Rare” Campaign

November 18, 2020 - Today, the Black Women’s Health Imperative (BWHI) announced the launch of a comprehensive multi-channel campaign entitled RISE for Rare (#riseforrare). 
Travere Circle Logo

Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.

SAN DIEGO, November 16, 2020 – Retrophin Inc., (NASDAQ: RTRX) today announced that the company has changed its global corporate name to Travere Therapeutics, Inc. Read the press release >
Travere Circle Logo

Travere Therapeutics: Our Brand Story

We come to work every day to do something extraordinary that can make a difference in the lives of the patients we serve. This is the core of who we are at Travere Therapeutics.
Travere Circle Logo

Retrophin Completes Acquisition of Orphan Technologies

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
Travere Circle Logo

Retrophin Reports Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2020 financial results and provided a corporate update. Read the press release >